|
Sep 26
|
Should We Be Delighted With Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 46%?
|
|
Sep 25
|
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
|
|
Jul 29
|
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
|
|
Jul 25
|
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
|
|
Jun 20
|
Collegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 19% CAGR over the last five years
|
|
Jun 13
|
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
|
|
Jun 10
|
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Upgraded by Jefferies
|
|
May 30
|
Insider Sale: EVP & CFO Colleen Tupper Sells Shares of Collegium Pharmaceutical Inc (COLL)
|
|
May 29
|
Collegium to Participate in Jefferies Global Healthcare Conference
|
|
May 13
|
Collegium Announces $35 Million Accelerated Share Repurchase Program
|
|
May 10
|
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay Packet
|
|
May 9
|
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
May 9
|
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
|
|
May 9
|
Collegium Reports First Quarter 2024 Financial Results
|
|
May 9
|
Collegium Announces CEO Transition
|
|
May 7
|
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
|
|
May 2
|
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Apr 29
|
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
|
|
Apr 29
|
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
|
|
Apr 25
|
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
|